Diagnostic performance of micro-ultrasound versus multiparametric mri for clinically significant prostate cancer in active surveillance: a diagnostic test accuracy meta-analysis
DOI:
https://doi.org/10.48193/1egdak18Keywords:
Prostate cancer, Active surveillance, Microultrasound, multiparametric MRI, diagnostic accuracyAbstract
Objective: To compare the diagnostic performance of micro-ultrasound (mUS) versus multiparametric MRI (mpMRI) for identifying clinically significant prostate cancer (csPCa) in patients under active surveillance (AS).
Methodology: We conducted a systematic review and diagnostic test accuracy meta-analysis following PRISMA-DTA and the Cochrane Handbook for Diagnostic Reviews. Five databases were searched on November 22, 2024. Studies were eligible if they directly compared mUS and mpMRI in AS patients and provided extractable 2×2 diagnostic data. Pooled sensitivity, specificity, diagnostic odds ratios (DOR), and area under the curve (AUC) were estimated using bivariate random-effects models.
Results: Five studies comprising 339 AS patients met inclusion criteria. Pooled sensitivity of mUS was 96.2% (95% CI 90.2–98.5), compared with 87.8% (95% CI 70.7–95.5) for mpMRI. Specificity was 41.6% (95% CI 28.4–56.1) for mUS and 47.3% (95% CI 27.7–67.8) for mpMRI. AUC values were 0.84 for mUS and 0.79 for mpMRI (p = 0.73). DORs were similar (mUS: 9.9; mpMRI: 8.3). No major heterogeneity or publication bias was observed. Risk of bias ranged from moderate to serious across studies.
Limitations: Only five studies were included, two available solely as abstracts. Heterogeneity in csPCa definitions, imaging protocols, and biopsy techniques may limit generalizability.
Originality / Value: This is the first diagnostic meta-analysis focused exclusively on AS patients directly comparing mUS and mpMRI.
Conclusions: mUS demonstrates comparable diagnostic performance to mpMRI for detecting csPCa in AS patients, with slightly higher pooled sensitivity. These findings support mUS as a promising, accessible imaging alternative in AS pathways
References
1. Briganti A, Fossati N, Catto JWF, Cornford P, Montorsi F, Mottet N, et al. Active Surveillance for Low-risk Prostate Cancer: The European Association of Urology Position in 2018. European Urology. 2018;74(3): 357–368. https://doi.org/10.1016/j.eururo.2018.06.008.
2. Chappidi MR, Lin DW, Westphalen AC. Role of MRI in Active Surveillance of Prostate Cancer. Seminars in Ultrasound, CT and MRI. 2025;46(1): 31–44. https://doi.org/10.1053/j.sult.2024.11.002.
3. Pavlovich CP, Cornish TC, Mullins JK, Fradin J, Mettee LZ, Connor JT, et al. High-resolution transrectal ultrasound: Pilot study of a novel technique for imaging clinically localized prostate cancer. Urologic Oncology: Seminars and Original Investigations. 2014;32(1): 34.e27-34.e32. https://doi.org/10.1016/j.urolonc.2013.01.006.
4. Tan GH, Wodlinger B, Pavlovich C, Klotz L. Comparing Micro-Ultrasound to mpMRI in Detecting Clinically Significant Prostate Cancer. Société Internationale d’Urologie Journal. 2022;3(1). https://doi.org/10.48083/DHNC9428.
5. Hofbauer SL, Luger F, Harland N, Plage H, Reimann M, Hollenbach M, et al. A non‐inferiority comparative analysis of micro‐ultrasonography and MRI‐targeted biopsy in men at risk of prostate cancer. BJU International. 2022;129(5): 648–654. https://doi.org/10.1111/bju.15635.
6. Ghai S, Eure G, Fradet V, Hyndman ME, McGrath T, Wodlinger B, et al. Assessing Cancer Risk on Novel 29 MHz Micro-Ultrasound Images of the Prostate: Creation of the Micro-Ultrasound Protocol for Prostate Risk Identification. Journal of Urology. 2016;196(2): 562–569. https://doi.org/10.1016/j.juro.2015.12.093.
7. Deeks JJ, Bossuyt PM, Leeflang MM, Takwoingi Y, [eds]. Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy.. 1st edn Wiley; 2023. https://doi.org/10.1002/9781119756194.
8. McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM, and the PRISMA-DTA Group, et al. Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. JAMA. 2018;319(4): 388. https://doi.org/10.1001/jama.2017.19163.
9. Whiting PF, Rutjes AWS, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies. Annals of Internal Medicine. 2011;155(8): 529–536. https://doi.org/10.7326/0003-4819-155-8-201110180-00009.
10. R Core Team. A Language and Environment for Statistical Computing. R Foundation for Statistical Computing. 2024.
11. Schwarzer G. meta: General Package for Meta-Analysis. 2026. https://cran.r-project.org/web/packages/meta/index.html
12. Viechtbauer W. metafor: Meta-Analysis Package for R. 2026. https://cran.r-project.org/web/packages/metafor/index.html
13. Doebler P, Sousa-Pinto B. mada: Meta-Analysis of Diagnostic Accuracy. 2025. https://cran.r-project.org/web/packages/mada/index.html
14. Noma H. dmetatools: Computational Tools for Meta-Analysis of Diagnostic Accuracy Test. 2023. https://cran.r-project.org/web/packages/dmetatools/index.html
15. Reitsma JB, Glas AS, Rutjes AWS, Scholten RJPM, Bossuyt PM, Zwinderman AH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. Journal of Clinical Epidemiology. 2005;58(10): 982–990. https://doi.org/10.1016/j.jclinepi.2005.02.022.
16. Bates D, Maechler M, Bolker [cre B, aut, Walker S, Ly A, et al. lme4: Linear Mixed-Effects Models using ‘Eigen’ and S4. 2026. https://cran.r-project.org/web/packages/lme4/index.html
17. Eure G, Fanney D, Lin J, Wodlinger B, Ghai S. Comparison of conventional transrectal ultrasound, magnetic resonance imaging, and micro-ultrasound for visualizing prostate cancer in an active surveillance population: A feasibility study. Canadian Urological Association Journal = Journal De l’Association Des Urologues Du Canada. 2019;13(3): E70–E77. https://doi.org/10.5489/cuaj.5361.
18. Staerman F. The utility of 29 MHz high resolution micro-ultrasound and mpMRI in the management of Gleason six prostate cancer with active surveillance. European Urology Supplements. 2019;18(11): e3502. https://doi.org/10.1016/S1569-9056(19)34656-1.
19. Maffei D, Fasulo V, Avolio PP, Saitta C, Paciotti M, De Carne F, et al. Diagnostic performance of microUltrasound at MRI‐guided confirmatory biopsy in patients under active surveillance for low‐risk prostate cancer. The Prostate. 2023;83(9): 886–895. https://doi.org/10.1002/pros.24532.
20. Albers P, Wang B, Broomfield S, Medina Martín A, Fung C, Kinnaird A. Micro-ultrasound Versus Magnetic Resonance Imaging in Prostate Cancer Active Surveillance. European Urology Open Science. 2022;46: 33–35. https://doi.org/10.1016/j.euros.2022.09.019.
21. Albers PS, Wang B, Broomfield S, Martin AM, Metcalfe P, Tu W, et al. MP19-18 Microultrasound in cancer-active surveillance (Music-As). Journal of Urology. 2024;211(5S). https://doi.org/10.1097/01.JU.0001008716.22569.77.18.
22. Lee CH, Tan TW, Tan CH. Multiparametric MRI in Active Surveillance of Prostate Cancer: An Overview and a Practical Approach. Korean Journal of Radiology. 2021;22(7): 1087. https://doi.org/10.3348/kjr.2020.1224.
23. Avolio PP, Lughezzani G, Paciotti M, Maffei D, Uleri A, Frego N, et al. The use of 29 MHz transrectal micro-ultrasound to stratify the prostate cancer risk in patients with PI-RADS III lesions at multiparametric MRI: A single institutional analysis. Urologic Oncology: Seminars and Original Investigations. 2021;39(12): 832.e1-832.e7. https://doi.org/10.1016/j.urolonc.2021.05.030.
24. Cotter F, Perera S, Sathianathen N, Lawrentschuk N, Murphy D, Bolton D. Comparing the Diagnostic Performance of Micro-Ultrasound-Guided Biopsy Versus Multiparametric Magnetic Resonance Imaging-Targeted Biopsy in the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-Analysis. Société Internationale d’Urologie Journal. 2023; 465. https://doi.org/10.48083/DSVY1863.
25. Eastham JA, Auffenberg GB, Barocas DA, Chou R, Crispino T, Davis JW, et al. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part II: Principles of Active Surveillance, Principles of Surgery, and Follow-Up. Journal of Urology. 2022;208(1): 19–25. https://doi.org/10.1097/JU.0000000000002758.
26. European Association of Urology. EAU Guidelines on Prostate Cancer - Uroweb. 2024
27. Sonn GA, Fan RE, Ghanouni P, Wang NN, Brooks JD, Loening AM, et al. Prostate Magnetic Resonance Imaging Interpretation Varies Substantially Across Radiologists. European Urology Focus. 2019;5(4): 592–599. https://doi.org/10.1016/j.euf.2017.11.010.
28. Greer MD, Brown AM, Shih JH, Summers RM, Marko J, Law YM, et al. Accuracy and agreement of PIRADSv2 for prostate cancer mpMRI: A multireader study. Journal of magnetic resonance imaging: JMRI. 2017;45(2): 579–585. https://doi.org/10.1002/jmri.25372.
29. Barentsz JO, Richenberg J, Clements R, Choyke P, Verma S, Villeirs G, et al. ESUR prostate MR guidelines 2012. European Radiology. 2012;22(4): 746–757. https://doi.org/10.1007/s00330-011-2377-y.
30. Rosenkrantz AB, Ginocchio LA, Cornfeld D, Froemming AT, Gupta RT, Turkbey B, et al. Interobserver Reproducibility of the PI-RADS Version 2 Lexicon: A Multicenter Study of Six Experienced Prostate Radiologists. Radiology. 2016;280(3): 793–804. https://doi.org/10.1148/radiol.2016152542.
31. Leeflang MMG, Rutjes AWS, Reitsma JB, Hooft L, Bossuyt PMM. Variation of a test’s sensitivity and specificity with disease prevalence. CMAJ: Canadian Medical Association journal = journal de l’Association medicale canadienne. 2013;185(11): E537-544. https://doi.org/10.1503/cmaj.121286.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Revista Mexicana de Urología

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

